An announcement from Quanterix ( (QTRX) ) is now available.
On March 3, 2025, Quanterix announced its proposed acquisition of Akoya Biosciences, aimed at creating the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. The acquisition is expected to expand Quanterix’s market opportunities significantly, particularly in Alzheimer’s Disease diagnostics, and generate substantial cost synergies. The merger is anticipated to close in the second quarter of 2025, pending shareholder approvals. Additionally, Quanterix addressed the nomination of three candidates by Kent Lake Partners for its Board of Directors, emphasizing the strategic importance of the Akoya acquisition despite Kent Lake’s objections.
More about Quanterix
Quanterix Corporation is a company focused on scientific discovery through ultra-sensitive biomarker detection. It offers precision instruments, digital immunoassay technology, and a CLIA-certified laboratory, supporting research in neurology, oncology, immunology, cardiology, and infectious disease. Quanterix’s Simoa® technology is known for its unparalleled sensitivity in detecting proteins at levels lower than the Level of Quantification (LoQ).
YTD Price Performance: -29.46%
Average Trading Volume: 696,261
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $292.4M
For an in-depth examination of QTRX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com